Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. Its products and services cover bio research solutions, such as stem cells primary cells and media, cell culture, transfection, exosomes, and assay solutions; electrophoresis of nucleic acids and proteins; primary and stem cell protocols; Hepatocytes/ADMETox solutions for microsomes and primary cell culture applications; and CytoSMART system, a live cell imaging and monitoring system. The company's products and services also cover pharma and biotech solutions, such as bioprocess systems, drug discovery, endotoxin detection, informatics, bioassay services, and encapsulation technologies; consumer health solutions comprising hygiene, nutrition, personal care, preservation, and capsules and food supplements; and agro ingredients, such as intermediates, molluscicides, specialties, formulation ingredients, crop protection, and animal care solutions. In addition, its products and services include coatings and composites, performance intermediates, composite materials, and functional chemicals; and materials protection, oil and gas, marine antifouling, hydrazine, and wood protection solutions. The company serves pharmaceutical, biotech, consumer health, nutrition, and specialty chemicals and industrial markets. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Read More
